‘Pretty drastic increases;' Higher flu cases putting hospitals in tough spot
[DOWNLOAD: Free WHIO-TV News app for alerts as news breaks]
News Center 7′s Xavier Hershovitz reports on the latest spike in cases and new warning from doctors and hospitals this morning on News Center 7 Daybreak from 4:25 a.m. through 7 a.m.
TRENDING STORIES:
Cause of death released for former OSU player found dead in his apartment
UPDATE: Semi hits utility pole, rolls over; part of busy road closed
Can you help? Police looking for suspect accused of using stolen credit card
More people are getting sick.
Outpatient visits are up 34 percent in a week. This includes visits to a primary care doctor or urgent care.
'Just really over the last couple of weeks, we've seen pretty drastic increases,' said Lisa Henderson with the Greater Dayton Area Hospital Association. 'We are seeing definitely a higher than-usual flu and respiratory illness season.'
We will update this story.
[SIGN UP: WHIO-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
A farewell to Ozzy, Coke's sugar high, another vaccine shake-up: The week in review
RFK shakes up vaccines again Health Secretary Robert F. Kennedy Jr. took another step toward overhauling the nation's vaccine policy when he approved the removal of thimerosal, a mercury-based preservative, from all flu vaccines despite widespread agreement in the medical community that the preservative is safe. Kennedy signed off on a recommendation from the Advisory Committee on Immunization Practices, a panel he replaced with his own appointed members in June, to stop distributing vaccines containing thimerosal, which has long been targeted by anti-vaccine groups. An operatic honor for Melania Republican lawmakers are working on a Kennedy Center production of their own: renaming the center's Opera House to the 'First Lady Melania Trump Opera House.' The House Appropriations Committee, whose spending bill funds the iconic performing arts venue in Washington, voted 33-25 for the change. Lawmakers have already agreed to spend $256.7 million on improvements to the center sought by President Donald Trump, who ousted much of the Kennedy Center's board after he took office and appointed himself chairman. He has criticized some of the center's performances and said in one visit that he 'never liked 'Hamilton' very much.' A sweet twist to the Cola wars Cane sugar: It's the real thing. A Coca-Cola made with cane sugar − not high-fructose corn syrup − is coming to the United States this fall, the company announced, just like the Coke you find overseas, including Mexico. (The long-running debate over which tastes better, U.S. Coke or Mexican Coke, has been a fierce one). The news doesn't come as a compete surprise; President Donald Trump had made a case for cane sugar Coke on social media in mid-July − 'You'll see. It's just better!' Also, not to be outdone, Pepsi announced it is launching Pepsi Prebiotic Cola this fall, in Original Cola and Cherry Vanilla, containing 5 grams of cane sugar and 3 grams of prebiotic fiber. Ozzy Osbourne, the 'Prince of Darkness,' is dead The heavy metal world has lost one of its most beloved characters, Ozzy Osbourne, at age 76, only weeks after reuniting with his original band, Black Sabbath, in England for a farewell show. Osbourne, who was infamous for his hard living (and for biting the head off a bat), exploded into stardom in a solo career and later branched into reality TV with MTV's 'The Osbournes' in the early 2000s. In 2020, he revealed he had Parkinson's disease. In a just-announced new memoir, 'Last Rites,' arriving Oct. 7, Osbourne says: 'Look, if it ends tomorrow, I can't complain. I've been all around the world. … I've done good, and I've done bad. But right now, I'm not ready to go anywhere.' Remembering Ozzy Osbourne: Life on the 'Crazy Train': The metal icon through the years All bets for 2026 are on Scottie Scheffler Scottie Scheffler, fresh off a dominating win at the British Open July 20, is at the top of his game, and you can expect he'll be there for awhile. Scheffler, 29, who also captured the PGA Championship in May and now needs only a U.S. Open victory to enter the elite group of golfers who have won the sport's grand slam of all four major championships, is now the odds-on favorite to win every major in 2026, according to BetMGM. Declared the gaming venture's Matt Wall: 'The comparisons with Tiger Woods certainly don't look out of place right now.' − Compiled by Robert Abitbol This article originally appeared on USA TODAY: A farewell to Ozzy, Coke's sugar high, the flu fight: Week in review
Hamilton Spectator
3 days ago
- Hamilton Spectator
Microbix Exhibiting & Presenting at ADLM
MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine ('ADLM') conference taking place in Chicago, Illinois July 28 to 31, 2025. At ADLM, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of many infectious and other diseases. Microbix will thereby showcase its ever-growing portfolio of quality assessment products ('QAPs™') that help ensure the accuracy of antigen and molecular (i.e., 'PCR' or 'NAAT') tests and their workflows. Microbix will also be meeting with many current and prospective clients to determine how best to support their quality management system needs. Also at ADLM, Microbix will present results of a pilot External Quality Assessment (EQA) program enabled by Microbix QAPs. Its poster is titled 'Quality Control Rapid Response in Pre-Pandemic Preparedness Showcasing a Synthetic H5N1 Genetic Template.' which reviews the performance of novel QAPs for answering the critical question of whether pre-existing molecular tests for Influenza A can accurately detect the emerging H5N1 (Bird Flu) pandemic strain. A Microbix customer and collaborator, American Proficiency Institute ('API'), is presenting a related poster titled 'Evaluation of NAAT Recovery of Highly Pathogenic Avian Influenza A (H5N1) Clade 2.3.4.4b from Novel Proficiency Samples.' After each poster is presented at ADLM, they will be made available at . The two posters detail the results of work first announced on January 13, 2025, whereby Microbix and API disclosed the creation of QAPs and a pilot proficiency testing program for evaluating the performance of Flu tests in detecting H5N1. As widely reported in the media, H5N1 Flu is a novel variant for which the human population does not have established immunity. Accordingly, H5N1 Flu has pandemic potential, with it having thus far caused severe disease or death in approximately 50% of those persons infected. Microbix gratefully acknowledges the vital role of API in helping to conduct this societally important work. Amer Alagic, Microbix's Director of R&D and lead author of its poster commented, 'Working alongside API, our team is privileged to help answer vital questions concerning the accuracy and usefulness of currently available Flu tests for detecting H5N1. Microbix's novel H5N1 QAPs were created by our team to ensure full genetic coverage of a potential pandemic strain and were made safely under Microbix IP and with cutting-edge synthetic biology techniques. H5N1 QAPs are fully-characterized, accurately-quantified, and are available in liquid and FLOQSwab formats to support both lab-based and point-of-care assays. These Microbix capabilities can be rapidly deployed in response to any emerging pandemic.' Purchase enquiries for these or other Microbix QAPs can be e-mailed to . About Microbix Biosystems Inc. Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency-testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking Information This news release includes 'forward-looking information,' as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of API, the pilot proficiency testing program, the H5N1 QAPs, or their relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, access and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information. Please visit or for recent Microbix news and filings. For further information, please contact Microbix at: Copyright © 2025 Microbix Biosystems Inc. Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems Inc. FLOQ® and FLOQSwab® are trademarks of Copan Italia S.p.A. Other companies' names and products are protected by their respective trademarks.
New York Times
4 days ago
- New York Times
Kennedy Rescinds Endorsements for Some Flu Vaccines
Health Secretary Robert F. Kennedy Jr. on Tuesday formally rescinded federal recommendations for all flu vaccines containing thimerosal, a mercury-based preservative that the anti-vaccine movement has falsely linked to autism. The decision cements a move last month by vaccine advisers whom Mr. Kennedy named to the federal Advisory Committee on Immunization Practices after abruptly firing all 17 previous members. After hearing a presentation by the former leader of an anti-vaccine group, the panel had voted to walk back federal recommendations for all flu vaccines containing thimerosal. The decision will not affect most Americans seeking flu vaccines: Thimerosal is added to multidose vials of flu vaccines to prevent bacteria from growing, but it is not an ingredient of the single-dose vials administered to most people. During the 2024-25 respiratory virus season, only 3 percent of children and 2 percent of older adults received flu vaccines containing thimerosal, according to an analysis of electronic health records by Truveta, a company that analyzes such records. Still, multidose vials are needed in places where it is difficult to store many vaccines, such as nursing homes or mobile clinics serving remote rural areas. Mr. Kennedy's sign-off does not withdraw vaccines containing thimerosal from the market. But his rescinding the federal recommendation means that such shots may not be available to Americans, because insurance companies are no longer required to cover them. 'We urge global health authorities to follow this prudent example for the protection of children worldwide,' Mr. Kennedy said in a statement. Vaccine manufacturers have confirmed that they have the capacity to replace multidose vials containing mercury, ensuring that vaccine supplies for children and adults will 'remain uninterrupted,' the Department for Health and Human Services said in a statement. Federal health officials began removing thimerosal from childhood vaccines about 25 years ago, citing an abundance of caution despite a lack of data supporting safety concerns. Dozens of studies have shown thimerosal to be harmless. But the anti-vaccine community has long falsely maintained that the ingredient can cause neurological problems. At a meeting of the vaccine advisers last month, Lyn Redwood, a former leader of Children's Health Defense, the anti-vaccine group founded by Mr. Kennedy, claimed thimerosal was dangerous and toxic to children. Her presentation incorrectly said the only flu vaccine still containing thimerosal had 50 micrograms per dose, double the actual amount. The seven new advisers voted 5-1, with one abstention, to withdraw recommendations for flu vaccines containing thimerosal for children, pregnant women and other adults. The director of the Centers for Disease Control and Prevention typically accepts the recommendations of the committee. But the agency does not currently have a leader, and so the decision fell to Mr. Kennedy.
